TBCRC 035 UAB 15114: Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II Study with Pharmacodynamics Markers (TBCRC 35)

Grant

Date/time Interval

  • October 19, 2016 - August 29, 2018
  • Total Award Amount

  • 19526.00
  • Direct Costs

  • 15496.00
  • Sponsor Award Id

  • Contributor

  • Erica Stringer-Reasor M.D.   Investigator